{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T07:48:45Z","timestamp":1794210525920,"version":"4.8.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Orchard Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Metachromatic leukodystrophy (MLD) is an autosomal recessive lysosomal disorder caused by mutations in the arylsulfatase A gene. Until now, there has been little information on the burden of MLD on patients and their caregivers. This multinational study aims to quantify caregiver-related impacts of MLD across several key domains including symptoms, treatment burden, time investment, social and emotional well-being, and professional and financial impact.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Data were collected through moderator-assisted web survey and telephone interviews. The survey was developed with extensive input from clinical experts and MLD patient advocacy groups. The EQ-5D-5L questionnaire was administered during follow-up interviews. The total sample consisted of parents of MLD patients in the US (<jats:italic>n<\/jats:italic>\u2009=\u200910), France (<jats:italic>n<\/jats:italic>\u2009=\u200910), Germany (<jats:italic>n<\/jats:italic>\u2009=\u20096), UK (<jats:italic>n<\/jats:italic>\u2009=\u20095), Belgium (<jats:italic>n<\/jats:italic>\u2009=\u20091), and Norway (<jats:italic>n<\/jats:italic>\u2009=\u20092). The impact of MLD is evident from the EQ-5D-5L scores, which indicate utility values for caregivers below respective national population norms and a higher proportion of caregivers reporting problems with anxiety\/depression. Time involved for care was demonstrated by a mean of 4.1 inpatient and 29.6 outpatient hospital visits in the previous 12-month period. These commitments place stress on familial relationships with 50% of caregivers reporting their child\u2019s MLD diagnosis had negatively impacted their relationship with their spouse\/partner. Professionally, 76.5% of caregivers stopped working or switched to part-time employment following their child\u2019s MLD diagnosis, and most acknowledged caring for their child had affected their potential for career progression or promotion. Differences are also observed based on late infantile versus juvenile onset MLD, time since diagnosis, and for transplanted patients versus those who received palliative care only.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This multinational study demonstrates that MLD consistently negatively affects many aspects of caregivers\u2019 lives including health, relationships, and professional status, irrespective of location. We expect that the results of this study are generalizable to other countries. This study enhances our understanding of MLD caregiver impacts, which could improve patient care and assist in identifying support for individuals with MLD and their families.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02501-8","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T05:02:55Z","timestamp":1662094975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["An international study of caregiver-reported burden and quality of life in metachromatic leukodystrophy"],"prefix":"10.1186","volume":"17","author":[{"given":"Caroline","family":"Sevin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magalie","family":"Barth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Wilds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abena","family":"Afriyie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Walz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamarie","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Howie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9572-8779","authenticated-orcid":false,"given":"Francis","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"issue":"1","key":"2501_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/humu.22919","volume":"37","author":"M Cesani","year":"2016","unstructured":"Cesani M, et al. Mutation update of ARSA and PSAP genes causing metachromatic leukodystrophy. Hum Mutat. 2016;37(1):16\u201327.","journal-title":"Hum Mutat"},{"key":"2501_CR2","unstructured":"Lamichhane A, and F Rocha Cabrero Metachromatic Leukodystrophy, in StatPearls. 2021: Treasure Island (FL)."},{"key":"2501_CR3","unstructured":"Gomez-Ospina N, Arylsulfatase A deficiency. In: Adam V, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A. editors. GeneReviews((R)). Seattle, WA: University of Washington. (1993)."},{"key":"2501_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.576221","volume":"7","author":"AA Shaimardanova","year":"2020","unstructured":"Shaimardanova AA, et al. Metachromatic leukodystrophy: diagnosis, modeling, and treatment approaches. Front Med (Lausanne). 2020;7: 576221.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"2501_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13023-019-1060-2","volume":"14","author":"M Harrington","year":"2019","unstructured":"Harrington M, et al. Insights into the natural history of metachromatic leukodystrophy from interviews with caregivers. Orphanet J Rare Dis. 2019;14(1):89.","journal-title":"Orphanet J Rare Dis"},{"issue":"13","key":"2501_CR6","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1177\/0883073816656401","volume":"31","author":"FS Eichler","year":"2016","unstructured":"Eichler FS, et al. Metachromatic leukodystrophy: an assessment of disease burden. J Child Neurol. 2016;31(13):1457\u201363.","journal-title":"J Child Neurol"},{"key":"2501_CR7","doi-asserted-by":"crossref","unstructured":"Elg\u00fcn, Saskia, et al. Phenotypic variation between siblings with metachromatic leukodystrophy. Orphanet J Rare Diseases. 2019; 14(1): 1\u201310.","DOI":"10.1186\/s13023-019-1113-6"},{"key":"2501_CR8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13023-015-0313-y","volume":"10","author":"AA Boucher","year":"2015","unstructured":"Boucher AA, et al. Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report. Orphanet J Rare Dis. 2015;10:94.","journal-title":"Orphanet J Rare Dis"},{"key":"2501_CR9","unstructured":"European medicines agency. Libmeldy. 2020; Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/libmeldy."},{"issue":"1","key":"2501_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s41687-019-0140-3","volume":"3","author":"M Harrington","year":"2019","unstructured":"Harrington M, et al. Assessing the impact on caregivers caring for patients with rare pediatric lysosomal storage diseases: development of the caregiver impact questionnaire. J Patient Rep Outcomes. 2019;3(1):44.","journal-title":"J Patient Rep Outcomes"},{"issue":"Suppl 1","key":"2501_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10198-016-0787-0","volume":"17","author":"M P\u00e9ntek","year":"2016","unstructured":"P\u00e9ntek M, Gul\u00e1csi L, Brodszky V, et al. Social\/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe. Eur J Health Econ. 2016;17(Suppl 1):89\u201398. https:\/\/doi.org\/10.1007\/s10198-016-0787-0.","journal-title":"Eur J Health Econ"},{"key":"2501_CR12","doi-asserted-by":"publisher","unstructured":"Morrison A, Oussoren E, Friedel T, Cruz J, Yilmaz N. Pathway to diagnosis and burden of illness in mucopolysaccharidosis type VII - a European caregiver survey. Orphanet J Rare Dis. 2019;14(1):254. https:\/\/doi.org\/10.1186\/s13023-019-1233-z","DOI":"10.1186\/s13023-019-1233-z"},{"key":"2501_CR13","doi-asserted-by":"publisher","unstructured":"Pokrzywinski R, Hareendran A, Nalysnyk L, et al. Impact and burden of acid sphingomyelinase deficiency from a patient and caregiver perspective. Sci Rep. 2021;11(1):20972. https:\/\/doi.org\/10.1038\/s41598-021-99921-6.","DOI":"10.1038\/s41598-021-99921-6."},{"issue":"10","key":"2501_CR14","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res"},{"issue":"5","key":"2501_CR15","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B van Hout","year":"2012","unstructured":"van Hout B, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708\u201315.","journal-title":"Value Health"},{"key":"2501_CR16","unstructured":"EuroQol research foundation. Crosswalk index value calculator. 2019; Available from: https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-5l-about\/valuation-standard-value-sets\/crosswalk-index-value-calculator\/."},{"key":"2501_CR17","doi-asserted-by":"crossref","unstructured":"A Szende, B Janssen, and J Cabases. Self-Reported population health: an international perspective based on EQ-5D, ed. 2014, Dordrecht (NL): Springer.","DOI":"10.1007\/978-94-007-7596-1"},{"issue":"1","key":"2501_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13023-021-01828-y","volume":"16","author":"L Ammann-Schnell","year":"2021","unstructured":"Ammann-Schnell L, et al. The impact of severe rare chronic neurological disease in childhood on the quality of life of families-a study on MLD and PCH2. Orphanet J Rare Dis. 2021;16(1):211.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2501_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s41687-018-0041-x","volume":"2","author":"TM Brown","year":"2018","unstructured":"Brown TM, et al. Development of the impact of juvenile metachromatic leukodystrophy on physical activities scale. J Patient Rep Outcomes. 2018;2(1):15.","journal-title":"J Patient Rep Outcomes"},{"key":"2501_CR20","doi-asserted-by":"publisher","unstructured":"Keller, Stephanie R, et al, Practical approaches and knowledge gaps in the care for children with leukodystrophies. J Child Neurol. 2021; 36(1): 65\u201378 https:\/\/doi.org\/10.1177\/0883073820946154.","DOI":"10.1177\/0883073820946154"},{"issue":"5","key":"2501_CR21","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1177\/0883073809341669","volume":"25","author":"A Mahmood","year":"2010","unstructured":"Mahmood A, Berry J, et al. Metachromatic leukodystrophy: a case of triplets with the late infantile variant and a systematic review of the literature. J Child Neurol. 2010;25(5):572\u201380.","journal-title":"J Child Neurol"},{"issue":"9","key":"2501_CR22","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/j.1469-8749.2011.04028.x","volume":"53","author":"C Kehrer","year":"2011","unstructured":"Kehrer C, et al. The natural course of gross motor deterioration in metachromatic leukodystrophy. Dev Med Child Neurol. 2011;53(9):850\u20135.","journal-title":"Dev Med Child Neurol"},{"key":"2501_CR23","doi-asserted-by":"publisher","unstructured":"Eicherl, et al. Caregiver perspective on the initial signs and symptoms of metachromatic leukodystrophy. 2021. Retrieved from ResearchGate: https:\/\/doi.org\/10.21203\/rs.3.rs-546822\/v1.","DOI":"10.21203\/rs.3.rs-546822\/v1"},{"issue":"1","key":"2501_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s10826-015-0219-2","volume":"25","author":"S Albuquerque","year":"2016","unstructured":"Albuquerque S, Pereira M, Narciso I. Couple\u2019s relationship after the death of a child: a systematic review. J Child Fam Stud. 2016;25(1):30\u201353.","journal-title":"J Child Fam Stud"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02501-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02501-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02501-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T05:13:06Z","timestamp":1662095586000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02501-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2501"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02501-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]},"assertion":[{"value":"14 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study protocol and all study material were approved by an external Institutional Review Board, Pearl IRB (Indianapolis, Indiana, USA). All participants consented to their anonymized data, including anonymized quotes and pseudonymized and\/or aggregated information to be used for this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data presented in this paper was collected as part of a study sponsored and funded by Orchard Therapeutics, Ltd., London, UK and was designed through a collaboration among the sponsor and Magnolia Innovation, LLC, Hoboken, NJ. \nData was collected by Magnolia Innovation. Dr. Sevin and Dr. Barth have no current conflicts of interest with Orchard nor Magnolia Innovation. Mr. Pang and Ms. Dillon are previous or current employees of sponsor, Orchard Therapeutics, Ltd. Ms. Afriyie, Mr. Howie, Mr. Walz, and Ms. Wilds are previous or current employees of Magnolia Innovation, LLC.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"329"}}